New Developments in Structural Heart Therapy: Attacking the Progression of Heart Failure Less Invasively

Join industry experts to learn more about Less Invasive Ventricular Enhancement™ (LIVE™) as a treatment option for reshaping the left ventricle to restore its pumping efficiency.

Stefan Anker, MD, PhD

Professor of Cardiology & Cachexia Research, Applied Cachexia Research, Dept. of Cardiology, Charité, Campus Virchow-Klinikum, Berlin, Germany

2012-14 President of the Heart Failure Association (HFA) of the European Society of Cardiology

Overview of current heart failure therapies and guidelines.

Prognosis for patients and limitations of optimal medical therapy, cardiac anker_paragraph_5: resynchronization therapy, LVAD’s, and status of heart transplantation.

Serenella Castelvecchio, MD

Cardiologist, Heart Failure Unit, I.R.C.C.S. Policlinico San Donato, Milan, Italy

Insights from the STICH trial: Patients that benefit from SVR.

Recent analysis of STICH showing Survival Benefit for SVR.

Andrew Wechsler, MD

Professor of Cardiothoracic Surgery, Drexel University College of Medicine, wechsler_paragraph_2: Philadelphia, PA, USA

Technology review of the LIVE™ procedure and the Revivent™ Myocardial Anchoring System

Phase I human clinical data.

Forthcoming transcatheter approach.